These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 36398557)
21. Similar therapeutic efficacy between a single administration of gene therapy and multiple administrations of recombinant enzyme in a mouse model of lysosomal storage disease. Ferla R; Claudiani P; Cotugno G; Saccone P; De Leonibus E; Auricchio A Hum Gene Ther; 2014 Jul; 25(7):609-18. PubMed ID: 24725025 [TBL] [Abstract][Full Text] [Related]
30. Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases. Li M Pediatr Ann; 2018 May; 47(5):e191-e197. PubMed ID: 29750286 [TBL] [Abstract][Full Text] [Related]
31. Lysosomal storage disorders: old diseases, present and future challenges. Klein AD; Futerman AH Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():59-63. PubMed ID: 24380123 [TBL] [Abstract][Full Text] [Related]
32. Treatment options for lysosomal storage disorders: developing insights. van Gelder CM; Vollebregt AA; Plug I; van der Ploeg AT; Reuser AJ Expert Opin Pharmacother; 2012 Nov; 13(16):2281-99. PubMed ID: 23009070 [TBL] [Abstract][Full Text] [Related]
33. Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I. Penati R; Fumagalli F; Calbi V; Bernardo ME; Aiuti A J Inherit Metab Dis; 2017 Jul; 40(4):543-554. PubMed ID: 28560469 [TBL] [Abstract][Full Text] [Related]
34. Treatment of lysosomal storage diseases: recent patents and future strategies. Ortolano S; Viéitez I; Navarro C; Spuch C Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):9-25. PubMed ID: 24433521 [TBL] [Abstract][Full Text] [Related]
35. Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID. Roca C; Motas S; Marcó S; Ribera A; Sánchez V; Sánchez X; Bertolin J; León X; Pérez J; Garcia M; Villacampa P; Ruberte J; Pujol A; Haurigot V; Bosch F Hum Mol Genet; 2017 Apr; 26(8):1535-1551. PubMed ID: 28334745 [TBL] [Abstract][Full Text] [Related]
36. Novel treatment for neuronopathic lysosomal storage diseases--cell therapy/gene therapy. Eto Y; Ohashi T Curr Mol Med; 2002 Feb; 2(1):83-9. PubMed ID: 11898850 [TBL] [Abstract][Full Text] [Related]
37. Large animal models contribute to the development of therapies for central and peripheral nervous system dysfunction in patients with lysosomal storage diseases. Gurda BL; Vite CH Hum Mol Genet; 2019 Oct; 28(R1):R119-R131. PubMed ID: 31384936 [TBL] [Abstract][Full Text] [Related]
38. Emerging therapies for neuropathic lysosomal storage disorders. Kelly JM; Bradbury A; Martin DR; Byrne ME Prog Neurobiol; 2017 May; 152():166-180. PubMed ID: 27725193 [TBL] [Abstract][Full Text] [Related]
39. Gene transfer strategies for correction of lysosomal storage disorders. D'Azzo A Acta Haematol; 2003; 110(2-3):71-85. PubMed ID: 14583667 [TBL] [Abstract][Full Text] [Related]